Natarajan Sethuraman - Sep 1, 2023 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role: Chief Scientific Officer
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Stock symbol: TRDA
Transactions as of: Sep 1, 2023
Transactions value $: -$6,494
Form type: 4
Date filed: 9/6/2023, 06:09 PM
Previous filing: Jul 12, 2023
Next filing: Mar 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRDA	Common Stock	Award	$0	+14.2K	+9.25%	$0.00	168K	Sep 1, 2023	Direct	F1
transaction	TRDA	Common Stock	Tax liability	-$6.49K	-449	-0.27%	$14.46	167K	Sep 5, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRDA	Stock Option (Right to Buy)	Award	$0	+21.5K		$0.00	21.5K	Sep 1, 2023	Common Stock	21.5K	$15.41	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
F2	This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
F3	25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.